BioXcel Therapeutics (BTAI) Enterprise Value (2022 - 2025)
Historic Enterprise Value for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$37.3 million.
- BioXcel Therapeutics' Enterprise Value rose 759.4% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.3 million, marking a year-over-year increase of 759.4%. This contributed to the annual value of -$29.9 million for FY2024, which is 5422.64% up from last year.
- BioXcel Therapeutics' Enterprise Value amounted to -$37.3 million in Q3 2025, which was up 759.4% from -$18.6 million recorded in Q2 2025.
- BioXcel Therapeutics' 5-year Enterprise Value high stood at -$18.6 million for Q2 2025, and its period low was -$233.5 million during Q2 2022.
- In the last 4 years, BioXcel Therapeutics' Enterprise Value had a median value of -$74.1 million in 2024 and averaged -$106.4 million.
- Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Enterprise Value was 6699.01% (2025), while the steepest drop was 759.4% (2025).
- Quarter analysis of 4 years shows BioXcel Therapeutics' Enterprise Value stood at -$193.7 million in 2022, then surged by 66.33% to -$65.2 million in 2023, then skyrocketed by 54.23% to -$29.9 million in 2024, then fell by 25.01% to -$37.3 million in 2025.
- Its Enterprise Value stands at -$37.3 million for Q3 2025, versus -$18.6 million for Q2 2025 and -$31.0 million for Q1 2025.